Eutilex.Co.,Ltd

Equities

A263050

KR7263050007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
2,105 ^KRW	-0.24%		+1.94%	-37.72%

05-16	Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-21	Eutilex.Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Eutilex Co.,Ltd. announced that it has received KRW 29 billion in funding

May 03, 2020

On May 4, 2020, Eutilex Co.,Ltd. (KOSDAQ:A263050) closed the transaction.

Latest news about Eutilex.Co.,Ltd

Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
Eutilex.Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Eutilex.Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Eutilex.Co.,Ltd(KOSDAQ:A263050) dropped from S&P Global BMI Index	18/09/23	CI
Eutilex.Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Eutilex.Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Eutilex.Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
Eutilex.Co.,Ltd. announced that it has received KRW 22.5003376 billion in funding	19/05/21	CI
Eutilex.Co.,Ltd. announced that it expects to receive KRW 22.5003376 billion in funding	11/05/21	CI
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA	27/01/21	CI
Eutilex.Co.,Ltd. announced that it has received KRW 19.9998552 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., Asset One	29/10/20	CI
Eutilex.Co.,Ltd. announced that it expects to receive KRW 19.9998552 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., Asset One	21/10/20	CI
Eutilex Co.,Ltd. announced that it has received KRW 29 billion in funding	03/05/20	CI
Eutilex Co.,Ltd. announced that it expects to receive KRW 29 billion in funding	23/04/20	CI
CDMO business GenScript ProBio and Eutilex Co., Ltd. Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for Car-T Programs	07/04/20	CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index	24/06/19	CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index	24/06/19	CI
Eutilex Co.,Ltd.(KOSDAQ:A263050) added to S&P Global BMI Index	24/06/19	CI
Eutilex Co.,Ltd. has completed an IPO in the amount of KRW 36.35 billion.	19/12/18	CI
Eutilex Co.,Ltd. has filed an IPO.	18/09/18	CI
Eutilex Co. Ltd Announces A Strategic Partnership with Zhejiang Huahai Pharmaceutical Ltd	06/11/17	CI
Zhejiang Huahai Pharma Enters into Licensing Agreement with Eutilex Co., Ltd	05/09/17	CI
Eutilex Co., Ltd. announced that it expects to receive CNY 196.64 million in funding from Zhejiang Huahai Pharmaceutical Co., Ltd.	31/08/17	CI
Eutilex Co., Ltd. announced that it has received KRW 21 billion in funding from DS Investment Management, Kolon Investment, Inc., G.N.TECH Venture Capital Co., Ltd., and other investors	07/12/16	CI
Eutilex Co. Ltd. Names Agustin de la Calle as Chief Business Officer	07/11/16	CI

Chart Eutilex.Co.,Ltd

Duration

Period

More charts

Company Profile

Eutilex Co., Ltd. is a Korea-based company mainly engaged in the production and sale of immunotherapy products. Major products include anticancer T cell therapies and antibody therapies.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
EUTILEX.CO.,LTD	-37.72%	56.01M
CSL LIMITED	-1.85%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
UCB	+62.17%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	9.11B
INNOVENT BIOLOGICS, INC.	-19.42%	7.32B

Biopharmaceuticals